April 2024
1. LIGHT GA, Swerdlow NR
   Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?
   Am J Psychiatry. 2024;181:272-274.
   

   >> Share

   
   March 2024
2. VAN DER PLUIJM M, Wengler K, Reijers PN, Cassidy CM, et al
   Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia.
   Am J Psychiatry. 2024 Mar 13:appiajp20220780. doi: 10.1176/appi.ajp.20220780.
   

   >> Share

   
   
3. VITA A, Barlati S, Ceraso A, Nibbio G, et al
   Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
   Am J Psychiatry. 2024 Mar 13:appiajp20230396. doi: 10.1176/appi.ajp.20230396.
   

   >> Share

   
   February 2024
4. HOU Y, Xia H, He T, Zhang B, et al
   N2 Responses in Youths With Psychosis Risk Syndrome and Their Association With Clinical Outcomes: A Cohort Follow-Up Study Based on the Three-Stimulus Visual Oddball Paradigm.
   Am J Psychiatry. 2024 Feb 29:appiajp20221013. doi: 10.1176/appi.ajp.20221013.
   

   >> Share

   
   
5. ROGNLI EB, Hoye A, Bramness JG
   Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.
   Am J Psychiatry. 2024;181:168-169.
   

   >> Share

   
   
6. ZHU L, Ni T, Guan F
   Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention.
   Am J Psychiatry. 2024;181:168.
   

   >> Share

   
   November 2023
7. SAWADA T, Barbosa AR, Araujo B, McCord AE, et al
   Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donor's Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia.
   Am J Psychiatry. 2023 Nov 2:appiajp20220723. doi: 10.1176/appi.ajp.20220723.
   

   >> Share

   
   
8. KALIN NH
   New Insights Into Psychotic Disorders.
   Am J Psychiatry. 2023;180:779-781.
   

   >> Share

   
   
9. VAN DER VEN E, Susser E
   Structural Racism and Risk of Schizophrenia.
   Am J Psychiatry. 2023;180:782-784.
   

   >> Share

   
   
10. CANNON TD
    Predicting Conversion to Psychosis Using Machine Learning: Are We There Yet?
    Am J Psychiatry. 2023;180:789-791.
    

    >> Share

    
    
11. GOFF DC, Roffman J, Holt DJ
    Another Step Toward the Prediction of Antipsychotic Treatment Response Using Functional Connectivity.
    Am J Psychiatry. 2023;180:787-788.
    

    >> Share

    
    
12. FORSYTH JK, Bearden CE
    Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction.
    Am J Psychiatry. 2023;180:792-804.
    

    >> Share

    
    
13. STRAWBRIDGE RJ, Graham N
    Dissecting the Genetic Relationship Between Schizophrenia and Cardiovascular Disease.
    Am J Psychiatry. 2023;180:785-786.
    

    >> Share

    
    
14. JOSHI Y, Swerdlow N, Light G
    Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh.
    Am J Psychiatry. 2023;180:841-842.
    

    >> Share

    
    October 2023
15. SMUCNY J, Davidson I, Carter CS
    Are We There Yet? Predicting Conversion to Psychosis Using Machine Learning.
    Am J Psychiatry. 2023 Oct 4:appiajp20220973. doi: 10.1176/appi.ajp.20220973.
    

    >> Share

    
    September 2023
16. RODEVAND L, Rahman Z, Hindley GFL, Smeland OB, et al
    Characterizing the Shared Genetic Underpinnings of Schizophrenia and Cardiovascular Disease Risk Factors.
    Am J Psychiatry. 2023 Sep 27:appiajp20220660. doi: 10.1176/appi.ajp.20220660.
    

    >> Share

    
    
17. KUMAR K, Modenato C, Moreau C, Ching CRK, et al
    Subcortical Brain Alterations in Carriers of Genomic Copy Number Variants.
    Am J Psychiatry. 2023;180:685-698.
    

    >> Share

    
    August 2023
18. CAO H, Lencz T, Gallego JA, Rubio JM, et al
    A Functional Connectome-Based Neural Signature for Individualized Prediction of Antipsychotic Response in First-Episode Psychosis.
    Am J Psychiatry. 2023 Aug 30:appiajp20220719. doi: 10.1176/appi.ajp.20220719.
    

    >> Share

    
    June 2023
19. VASSOS E
    What is the Link Between Substance-Induced Psychosis and Primary Psychotic Disorders?
    Am J Psychiatry. 2023;180:404-406.
    

    >> Share

    
    May 2023
20. ROGNLI EB, Heiberg IH, Jacobsen BK, Hoye A, et al
    Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder.
    Am J Psychiatry. 2023 May 3:appiajp22010076. doi: 10.1176/appi.ajp.22010076.
    

    >> Share

    
    
21. KALIN NH
    Treatment Issues Related to the Use of Psychedelics, Trichotillomania, Social Anxiety Disorder, Schizophrenia, and Opioid Use Disorder.
    Am J Psychiatry. 2023;180:321-324.
    

    >> Share

    
    
22. VINOGRADOV S, Meyer-Kalos P
    Treating Pathologies of the Will.
    Am J Psychiatry. 2023;180:331-333.
    

    >> Share

    
    
23. BUCHANAN RW, Kreyenbuhl J
    An Argument for Antipsychotic Polypharmacy.
    Am J Psychiatry. 2023;180:334-336.
    

    >> Share

    
    April 2023
24. DIENEL SJ, Fish KN, Lewis DA
    The Nature of Prefrontal Cortical GABA Neuron Alterations in Schizophrenia: Markedly Lower Somatostatin and Parvalbumin Gene Expression Without Missing Neurons.
    Am J Psychiatry. 2023 Apr 19:appiajp20220676. doi: 10.1176/appi.ajp.20220676.
    

    >> Share

    
    
25. JOSHI YB, Molina JL, Braff DL, Green MF, et al
    Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden.
    Am J Psychiatry. 2023 Apr 11:appiajp20220649. doi: 10.1176/appi.ajp.20220649.
    

    >> Share

    
    
26. ZWICKER A, Fullerton JM, Mullins N, Rice F, et al
    Polygenic Scores and Onset of Major Mood or Psychotic Disorders Among Offspring of Affected Parents.
    Am J Psychiatry. 2023;180:285-293.
    

    >> Share

    
    March 2023
27. TAIPALE H, Tanskanen A, Tiihonen J
    Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.
    Am J Psychiatry. 2023 Mar 22:appiajp20220446. doi: 10.1176/appi.ajp.20220446.
    

    >> Share

    
    
28. REDDY LF, Glynn SM, McGovern JE, Sugar CA, et al
    A Novel Psychosocial Intervention for Motivational Negative Symptoms in Schizophrenia: Combined Motivational Interviewing and CBT.
    Am J Psychiatry. 2023 Mar 9:appiajp20220243. doi: 10.1176/appi.ajp.20220243.
    

    >> Share

    
    
29. HASSERIS S, Albinana C, Vilhjalmsson BJ, Mortensen PB, et al
    Polygenic Risk and Episode Polarity Among Individuals With Bipolar Disorder.
    Am J Psychiatry. 2023;180:200-208.
    

    >> Share

    
    January 2023
30. BANERJEE D, Girirajan S
    Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort.
    Am J Psychiatry. 2023;180:11-13.
    

    >> Share

    
    
31. SHIMELIS H, Oetjens MT, Walsh LK, Wain KE, et al
    Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population.
    Am J Psychiatry. 2023;180:65-72.
    

    >> Share

    
    December 2022
32. BARBER G, Nemeroff CB, Siegel S
    A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability.
    Am J Psychiatry. 2022;179:892-896.
    

    >> Share

    
    November 2022
33. JONAS KG, Fochtmann LJ, Perlman G, Kane JM, et al
    Distinguishing the Effects of Lead-Time Bias and Duration of Untreated Psychosis.
    Am J Psychiatry. 2022;179:862-863.
    

    >> Share

    
    
34. SKUSE DH
    Early-Onset Psychosis and Autism Spectrum Disorder: Similar Rates of Deleterious Copy Number Variants, Yet Diverse Phenotypic Manifestations.
    Am J Psychiatry. 2022;179:798-799.
    

    >> Share

    
    
35. KALIN NH
    Polygenic Risk Scores and Genetics in Psychiatry.
    Am J Psychiatry. 2022;179:781-784.
    

    >> Share

    
    
36. O'KEEFFE D, Kinsella A, Waddington JL, Clarke M, et al
    Distinguishing the Effects of Lead-Time Bias and Duration of Untreated Psychosis: Reply to Jonas et al.
    Am J Psychiatry. 2022;179:863-864.
    

    >> Share

    
    
37. SIGSTROM R, Kowalec K, Jonsson L, Clements CC, et al
    Association Between Polygenic Risk Scores and Outcome of ECT.
    Am J Psychiatry. 2022;179:844-852.
    

    >> Share

    
    October 2022
38. SOLMI M, Taipale H, Holm M, Tanskanen A, et al
    Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.
    Am J Psychiatry. 2022 Oct 6:appiajp21121189. doi: 10.1176/appi.ajp.21121189.
    

    >> Share

    
    September 2022
39. GREGERSEN M, Mollegaard Jepsen JR, Rohd SB, Sondergaard A, et al
    Developmental Pathways and Clinical Outcomes of Early Childhood Psychotic Experiences in Preadolescent Children at Familial High Risk of Schizophrenia or Bipolar Disorder: A Prospective, Longitudinal Cohort Study - The Danish High Risk and Resilience
    Am J Psychiatry. 2022;179:628-639.
    

    >> Share

    
    
40. COTTER D, Healy C, Staines L, Mongan D, et al
    Broadening the Parameters of Clinical High Risk for Psychosis.
    Am J Psychiatry. 2022;179:593-595.
    

    >> Share

    
    August 2022
41. BROWNSTEIN CA, Douard E, Mollon J, Smith R, et al
    Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder.
    Am J Psychiatry. 2022 Aug 24:appiajp21111175. doi: 10.1176/appi.ajp.21111175.
    

    >> Share

    
    June 2022
42. PAUL SM, Yohn SE, Popiolek M, Miller AC, et al
    Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.
    Am J Psychiatry. 2022 Jun 27:appiajp21101083. doi: 10.1176/appi.ajp.21101083.
    

    >> Share

    
    April 2022
43. CHAND GB, Singhal P, Dwyer DB, Wen J, et al
    Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population.
    Am J Psychiatry. 2022 Apr 12:appiajp21070686. doi: 10.1176/appi.ajp.21070686.
    

    >> Share

    
    
44. O'KEEFFE D, Kinsella A, Waddington JL, Clarke M, et al
    20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis.
    Am J Psychiatry. 2022;179:288-297.
    

    >> Share

    
    
45. CHUNG DW, Geramita MA, Lewis DA
    Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia.
    Am J Psychiatry. 2022;179:277-287.
    

    >> Share

    
    
46. KALIN NH
    Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia.
    Am J Psychiatry. 2022;179:255-258.
    

    >> Share

    
    
47. MALLA A
    Reducing Duration of Untreated Psychosis: The Neglected Dimension of Early Intervention Services.
    Am J Psychiatry. 2022;179:259-261.
    

    >> Share

    
    
48. SOHAL VS
    Transforming Discoveries About Cortical Microcircuits and Gamma Oscillations Into New Treatments for Cognitive Deficits in Schizophrenia.
    Am J Psychiatry. 2022;179:267-276.
    

    >> Share

    
    March 2022
49. MANCINI V, Rochas V, Seeber M, Roehri N, et al
    Aberrant Developmental Patterns of Gamma-Band Response and Long-Range Communication Disruption in Youths With 22q11.2 Deletion Syndrome.
    Am J Psychiatry. 2022;179:204-215.
    

    >> Share

    
    January 2022
50. GANESH S, D'Souza DC
    Cannabis and Psychosis: Recent Epidemiological Findings Continuing the "Causality Debate".
    Am J Psychiatry. 2022;179:8-10.
    

    >> Share

    
    
51. SANCHEZ-RICO M, Limosin F, Hoertel N
    Is a Diagnosis of Schizophrenia Spectrum Disorder Associated With Increased Mortality in Patients With COVID-19?
    Am J Psychiatry. 2022;179:71-73.
    

    >> Share

    
    October 2021
52. KALIN NH
    Depression and Schizophrenia: Sleep, Medical Risk Factors, Biomarkers, and Treatment.
    Am J Psychiatry. 2021;178:881-884.
    

    >> Share

    
    
53. CANNON TD
    Do the Benefits of Early Intervention Services for Psychosis Generalize and Persist in the Real World?
    Am J Psychiatry. 2021;178:890-892.
    

    >> Share

    
    September 2021
54. KALIN NH
    Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities.
    Am J Psychiatry. 2021;178:779-782.
    

    >> Share

    
    August 2021
55. PARKER DA, Trotti RL, McDowell JE, Keedy SK, et al
    Auditory Oddball Responses Across the Schizophrenia-Bipolar Spectrum and Their Relationship to Cognitive and Clinical Features.
    Am J Psychiatry. 2021 Aug 19:appiajp202120071043.
    

    >> Share

    
    July 2021
56. POSSELT CM, Albert N, Nordentoft M, Hjorthoj C, et al
    The Danish OPUS Early Intervention Services for First-Episode Psychosis: A Phase 4 Prospective Cohort Study With Comparison of Randomized Trial and Real-World Data.
    Am J Psychiatry. 2021 Jul 28:appiajp202120111596.
    

    >> Share

    
    
57. WEISER M, Davis JM, Brown CH, Slade EP, et al
    Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs.
    Am J Psychiatry. 2021 Jul 14:appiajp202020111657.
    

    >> Share

    
    
58. MARDER SR
    Changing the Face of Schizophrenia.
    Am J Psychiatry. 2021;178:584-585.
    

    >> Share

    
    May 2021
59. JOSHI YB, Thomas ML, Braff DL, Green MF, et al
    Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.
    Am J Psychiatry. 2021 May 14:appiajp202020081212.
    

    >> Share

    
    
60. ANGLIN DM, Ereshefsky S, Klaunig MJ, Bridgwater MA, et al
    From Womb to Neighborhood: A Racial Analysis of Social Determinants of Psychosis in the United States.
    Am J Psychiatry. 2021 May 3:appiajp202020071091.
    

    >> Share

    
    
61. HONER WG
    Better Evidence for Pharmacological Maintenance Treatment in Nonaffective Psychoses: Implications for Relapse Prevention.
    Am J Psychiatry. 2021;178:369-371.
    

    >> Share

    
    
62. FERRARELLI F, Phillips ML
    Examining and Modulating Neural Circuits in Psychiatric Disorders With Transcranial Magnetic Stimulation and Electroencephalography: Present Practices and Future Developments.
    Am J Psychiatry. 2021;178:400-413.
    

    >> Share

    
    April 2021
63. AMSALEM D, Markowitz JC, Jankowski SE, Yang LH, et al
    Sustained Effect of a Brief Video in Reducing Public Stigma Toward Individuals With Psychosis: A Randomized Controlled Trial of Young Adults.
    Am J Psychiatry. 2021 Apr 26:appiajp202020091293.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share